Beacon Capital Management Inc (Ohio)’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Beacon Capital Management Inc (Ohio)’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-150	Closed	-$6K	–	143
2016 Q2	$6K	Hold	150	–	–	﹤0.01%	110
2016 Q1	$6K	Hold	150	–	–	﹤0.01%	131
2015 Q4	$8K	Hold	150	–	–	﹤0.01%	139
2015 Q3	$7K	Hold	150	–	–	﹤0.01%	151
2015 Q2	$9K	Hold	150	–	–	﹤0.01%	147
2015 Q1	$8K	Hold	150	–	–	﹤0.01%	167
2014 Q4	$8K	Hold	150	–	–	﹤0.01%	150
2014 Q3	$7K	Hold	150	–	–	﹤0.01%	164
2014 Q2	$7K	Hold	150	–	–	﹤0.01%	165
2014 Q1	$6K	Hold	150	–	–	﹤0.01%	168
2013 Q4	$6K	Buy	+150	New	+$5.38K	﹤0.01%	163

Other funds holding PBE

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SAM

SignalPoint Asset Management Springfield, Missouri $411M AUM 23.81% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

Traynor Capital Management Malvern, Pennsylvania $1.7B AUM 39.15% 1-Year Est. Return

CAS

Cue Advisory Services Phoenix, Arizona $167M AUM 18.62% 1-Year Est. Return

Beacon Capital Management Inc (Ohio)'s PBE Position: Q3 2016 in Review

Beacon Capital Management Inc (Ohio) sold out of Invesco Biotechnology & Genome ETF (PBE) in Q3 2016, closing a stake of 150 shares — an estimated $6K sold.

Beacon Capital Management Inc (Ohio) first reported a position in PBE in Q4 2013 and held it in 11 quarters. The position peaked at $9K in Q2 2015. 68 funds tracked by Wall St. Rank hold PBE as of Q3 2016.

Beacon Capital Management Inc (Ohio) reported no remaining Invesco Biotechnology & Genome ETF position as of Q3 2016 after selling out during the quarter.
Beacon Capital Management Inc (Ohio) sold 150 Invesco Biotechnology & Genome ETF shares in Q3 2016, an estimated $6K.
Beacon Capital Management Inc (Ohio) first reported a position in Invesco Biotechnology & Genome ETF in Q4 2013 and held it in 11 quarters.
Beacon Capital Management Inc (Ohio)'s Invesco Biotechnology & Genome ETF position peaked at $9K in Q2 2015.
68 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2016.

Based on Beacon Capital Management Inc (Ohio)'s 13F filing for Q3 2016, filed 11 Oct 2016.